A Clinical Trial to Evaluate the Effects of an Omega-3-containing Supplement on DHA and EPA Levels in the Blood
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorRevive Active
About this trial
This is a 12-week, hybrid, single-arm clinical trial designed to evaluate the effects of an omega-3-containing supplement (Omega Active) on DHA and EPA levels in the blood. Forty participants will take two capsules of the test product daily and complete study-specific questionnaires at Baseline, Week 4, Week 8, and Week 12, while also attending their local Quest Diagnostics Center at Baseline and Week 12 for blood biomarker testing.
The study will also assess participants' perceptions of the effects of the test product on cognitive performance, gastrointestinal symptoms, and overall health through self-reported questionnaires. There is no randomization or blinding; all participants will receive the active supplement for the full 12-week intervention period.
Eligibility criteria
Qualifiers
Be male or female.
Be aged 18-65.
Anyone in good general health.
Willing to avoid taking other supplements, prescription medications, or herbal remedies that target DHA or EPA levels in the body, for the duration of the study.
Disqualifiers
Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
Anyone on anticoagulants or antiplatelet therapy.
Anyone with a bleeding disorder.
Anyone with any allergies or sensitivities to any of the study product ingredients.
Trial design
Treatments tested in this trial
- Omega Active Supplement
Treatment groups
49 Participants
are divided into 1 treatment groupSponsors and collaborators
Revive Active
Lead sponsor
Citruslabs
Collaborator
Source ClinicalTrials.gov